Feb 24 (Reuters) - Australian Clinical Labs Ltd (ACL) :
- DOES NOT PLAN TO PROVIDE GUIDANCE FOR FY22 AT THIS TIME
- DURING 2H FY22, ACL ANTICIPATES TESTING FOR COVID TO CONTINUE TO MODERATE
- FINAL DIVIDEND WILL BE CONSIDERED AT FULL YEAR, BASED ON FINANCIAL PERFORMANCE, CAPITAL NEEDS AND CORPORATE ACTIVITY
- IN H2, ANTICIPATES REBOUND IN NON-COVID TESTING TO CONTINUE AS RESTRICTIONS ON ESSENTIAL SURGERIES EASE
News: ACL Australian Clinical Labs Expects COVID Testing To Continue To Moderate In H2
Add ACL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.29 |
Change
0.040(1.78%) |
Mkt cap ! $462.2M | |||
| Open | High | Low | Value | Volume |
| $2.27 | $2.31 | $2.27 | $565.2K | 246.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 35087 | $2.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.29 | 9330 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.30 |
Change
0.040 ( 2.25 %) |
||||
| Open | High | Low | Volume | ||
| $2.28 | $2.31 | $2.27 | 49603 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| ACL (ASX) Chart |